Sugi Predict

Sugi Predict / Compounds / SCHEMBL19974683

SCHEMBL19974683

SCHEMBL19974683

CC(C(=O)C(=O)NCC1CC1)N(C=O)c1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGIR P43119 7/20 0.42
▸ ALDH1A1 P00352 2/20 0.36
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ SIGMAR1 Q99720 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ OPRK1 P41145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974988 0.87 L3MBTL1 (0.39) PTGIRALDH1A1SIGMAR1LMNACYP2C19
SCHEMBL19975382 0.87 L3MBTL1 (0.39) PTGIRALDH1A1SIGMAR1LMNACYP2C19
SCHEMBL19975397 0.87 L3MBTL1 (0.39) PTGIRALDH1A1SIGMAR1LMNACYP2C19
SCHEMBL19974871 0.86 MEN1 (0.39) PTGIRALDH1A1KMT2AMEN1CYP3A4
SCHEMBL19974799 0.86 SMN1; SMN2 (0.35) PTGIRALDH1A1KMT2ASIGMAR1MEN1
SCHEMBL28315360 0.84 CYP2C19 (0.33) PTGIRALDH1A1KMT2ASIGMAR1MEN1
SCHEMBL28316085 0.84 CYP2C19 (0.33) PTGIRALDH1A1KMT2ASIGMAR1MEN1
SCHEMBL19975130 0.84 HPGD (0.42) PTGIRALDH1A1KMT2AMEN1LMNA
SCHEMBL21176277 0.83 PTGIR (0.41) PTGIRSIGMAR1CYP2C19
SCHEMBL19975512 0.81 PTGIR (0.40) PTGIRALDH1A1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 — — US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 — — US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 — — CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 — — US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 — — EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C PTGIR 540/4885ALDH1A1 2271/4885DDB1 1772/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C PTGIR 679/4885ALDH1A1 2673/4885DDB1 1579/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C PTGIR 540/4885ALDH1A1 2271/4885DDB1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.